US6165225A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change, processes for their manufacture, and methods for their use
Assignee: Islet Sheet Medical LLC
•
Filing: 1998-08-03
•
Granted: 2000-12-26
•
Expires: 2018-08-03
Abstract
Abstract Bioartificial implants and methods for their manufacture and use are described, particularly bioartificial pancreases. In particular, the implants may be thin sheets which enclose cells, may be completely biocompatible over extended periods of time and may not induce fibrosis. The high-density-cell-containing thin sheets are preferably completely retrievable, and have dimensions allowing maintenance of optimal tissue viability through rapid diffusion of nutrients and oxygen and also allowing rapid changes in the secretion rate of insulin and/or other bioactive agents in response to changing physiology. Implantations of living cells, tissue, drugs, medicines and/or enzymes, contained in the bioartificial implants may be made to treat and/or prevent disease.
Inventors
- 👤 Richard D. Antanavich
- 👤 Randel Dorian
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 05:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61F; A61F2/00; A61F2/02; A61F2/022; A61L; A61L27/00; A61L27/14; A61L27/20; A61L27/36; A61L27/3604; A61L27/38; A61P; A61P3/00; A61P3/08; A61P3/10
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
57 words
A viable, physiologically active and biocompatible cellular or tissue implant having (a) a total volume greater than 10 cubic millimeters, (b) a tissue or cell content of at least 10% by volume, and (c) dimensions permitting sufficient oxygen diffusion to sustain cell or tissue viability when the implant is implanted into a vascularized site in a patient.
Claim 2
Dependent Claim
57 words
A viable, physiologically active and biocompatible cellular or tissue implant having (a) a total volume greater than 10 cubic millimeters, (b) a tissue or cell content of at least 10% by volume, and (c) dimensions permitting sufficient oxygen diffusion to sustain cell or tissue viability when the implant is implanted into a vascularized site in a patient.
Claim 3
Dependent Claim
15 words
The implant of claim 1, wherein said total volume is at least 100 cubic millimeters.
Claim 4
Dependent Claim
15 words
The implant of claim 1, wherein said total volume is at least 500 cubic millimeters.
Claim 5
Dependent Claim
17 words
The implant of claim 1, wherein said tissue or cell content is at least 20% by volume.
Claim 6
Dependent Claim
17 words
The implant of claim 2, wherein said tissue or cell content is at least 35% by volume.
Claim 7
Dependent Claim
13 words
The implant of claim 1, wherein the implant has a thin sheet configuration.
Claim 8
Dependent Claim
16 words
The implant of claim 1, wherein the implant has a thickness of less than 400 μm.
Claim 9
Dependent Claim
10 words
The implant of claim 1, wherein the implant is retrievable.
Claim 10
Dependent Claim
45 words
The implant of claim 1, wherein the implant comprises (a) a core of living tissue and a first gelled alginate, surrounded by (b) one or more layers of a second gelled alginate, which may be the same as or different from said first gelled alginate.
Claim 11
Dependent Claim
18 words
The implant of claim 9, wherein said core further comprises one or more trophic factors or nurse cells.
Claim 12
Dependent Claim
13 words
The implant of claim 9, wherein said core further comprises a substrate material.
Claim 13
Dependent Claim
13 words
The implant of claim 9, where said core further comprises an antioxidant material.
Claim 14
Dependent Claim
13 words
The implant of claim 9, wherein said living tissue comprises islets of Langerhans.
Claim 15
Dependent Claim
37 words
A method of treating or preventing a disease which can be treated or prevented with an active agent secreted by a cell or tissue, comprising implanting the implant of claim 1 in a patient in need thereof.
Claim 16
Dependent Claim
40 words
A method of treating or preventing a disease which can be treated or prevented by catabolism of a disease-causing agent or substance in a cell or tissue, comprising implanting the implant of claim 1 in a patient in need thereof.
Claim 17
Dependent Claim
10 words
The method of claim 14, wherein said disease is diabetes.
Claim 18
Dependent Claim
15 words
The implant of claim 9, wherein said core further comprises trophic factors and nurse cells.
References Cited (Backward Citations)
US3093831A
Cited
US5141581A
Cited
US4282317A
Cited
US4241187A
Cited
US4391909A
Cited
US4424132A
Cited
US4322298A
Cited
US4378016A
Cited
US4402694A
Cited
US4686098A
Cited
US4696286A
Cited
US4699141A
Cited
US5182111A
Cited
US5283187A
Cited
US5284761A
Cited
US5106627A
Cited
US5156844A
Cited
US5158881A
Cited
US4892538A
Cited
US5015476A
Cited
US5116494A
Cited
US5270192A
Cited
US5385582A
Cited
US5222982A
Cited
US5370681A
Cited
US5260002A
Cited
US5573934A
Cited
US5429821A
Cited
WO1993024077A1
Cited
US5387237A
Cited
DE4229526A1
Cited
US5387327A
Cited
US5380526A
Cited
US5639275A
Cited
WO1995018583A1
Cited
US5510102A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-12-26 | 2004-06-26 | 2004-12-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-12-26 | 2008-06-26 | 2008-12-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-12-26 | 2012-06-26 | 2012-12-26 | $7700.00 | Window Closed / Lapsed |